Join 400+ experts from across pharma, biotech, and academia who will be attending the 4th Allogeneic Cell Therapies Summit in Boston on May 9-12, 2022.
Over the past decade, CAR-T cell therapies have revolutionized the field of cell therapy, demonstrating clear curative potential with autologous approaches. Now, the field is looking to take these treatments a step further, by delivering next generation products that are cheaper, safer, and more efficacious.
Increasingly, cell therapy developers are investing into allogeneic treatment approaches, due to their potential to reduce the cost of goods and increase the patient accessibility. Some companies have even discarded their autologous pipelines in favor of allogeneic product development, because of the steep prices associated with personalized therapeutics.
Allogeneic therapies are revolutionizing the field of cell therapy, overcoming current critical barriers around cost, production, and accessibility currently faced with autologous, personalized treatments.
With this in mind, Hanson Wade is hosting its 4th annual Allogeneic Cell Therapies Summit on May 9-12, 2022, in Boston.
The 4th Allogeneic Cell Therapies Summit is the leading event focused on advancing pre-clinical development, translation, manufacturing, supply, and storage of allogeneic cell therapies to improve the accessibility and efficacy of patient care worldwide.
Attend the 4th Annual Allogeneic Cell Therapies Summit
Attendees of the event will get to connect with 400+ experts from across the fields of cell therapy and regenerative medicine. Event presentations and on-site discussions will explore a diverse range of topics related to allogeneic cell therapies, including approaches for scalable manufacturing, standardizing cryopreservation, and clinical development best practices.
Discussions at the summit will include:
- Genetic modification strategies to improve cell function, persistence, potency and safety
- Promises and challenges of allogeneic therapies for solid tumors
- Optimizing pre-conditioning strategies to improve engraftment
- Achieving reproducibility and comparability in manufacture of allogeneic products
- Utilizing the appropriate process and equipment to achieve scalable manufacture
- Considering cold-chain logistics and cryopreservation requirements to ensure your product remains efficacious
- Advancing digitalization of delivery
Join this fast-evolving community to compare platform technologies that can improve durability and persistence, review the strategy for selecting gold-standard donor starting material, and learn about the latest developments in gene engineering.
Attended by hundreds of highly regarded cell therapy developers, attendees will be uniting in Boston to collaborate and share lessons learned. There will be a focus on streamlining scalable manufacturing processes, defining optimal cryopreservation conditions, and exploring the regulatory frameworks necessary to achieve the large-scale adoption of these novel treatments.
Event of the Year for Allogeneic Cell Therapy Developers
Showcasing the work of Allogene, Atara Biotherapeutics, Athersys, Cellectis, Celularity, ImmunityBio, and more, you won’t want to miss the most important meeting of the year for cell therapy developers.
Speakers for the 2022 summit are also world class. Confirmed presenters include the CSO of Allogene, the CTO of Celularity, the CSO of Celyad Oncology, the CEO of Exacis Therapeutics, and the CEO of Mesoblast, and many more.
Put simply, this exciting event to advance the development of allogeneic cell therapies, including but not limited to CAR-T, NK, TCR, macrophage, stem cell-based therapeutics, and beyond.
Click the image below to view registration details, because the excitement within this space is explosive.
